Abstract
More than a year after the COVID-19 pandemic has been declared, the need still exists for accurate, rapid, inexpensive and non-invasive diagnostic methods that yield high specificity towards the current and newly emerging SARS-CoV-2 strains. Several studies have since established saliva as a more amenable specimen type in early detection and viral load quantitation as compared to the nasopharyngeal swabs. Considering the limitations and high demand for COVID-19 testing, we have employed MALDI-ToF mass spectrometry for the analysis of 60 gargle samples from human donors and compared the spectra with their respective RT-PCR results. Several standards including isolated human serum immunoglobulins and controls such as pre-COVID-19 saliva and heat inactivated SARS-CoV-2 virus were simultaneously analyzed to provide a relative view of the saliva and viral proteome as they would appear in this works methodology. Five potential biomarker peaks were established that demonstrated high consistency with PCR positive samples. Overall, the agreement of these results with RT-PCR testing was no less than 90% for the studied cohort, which consisted of young and largely asymptomatic student athletes. Further investigation of the potential biomarker peaks is necessary, however, from a clinical standpoint, these results are promising for a rapid and inexpensive COVID-19 assay.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was generously supported by the Division of Research and Innovation Partnerships, Northern Illinois University
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Northern Illinois University IRB approval obtained August 12, 2020
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# co-first authors
Data Availability
Data will be made available as supplemental material with the peer-reviewed and accepted manuscript or upon request
Abbreviations
- ACE2
- angiotensin-converting enzyme 2
- AUC
- area under the curve
- COVID-19
- coronavirus disease 2019
- DTT
- dithiothreitol
- E Protein
- envelope protein
- EUA
- emergency use authorization
- FDA
- food and drug administration
- IgA
- immunoglobulin A
- IgG
- immunoglobulin G
- IgM
- immunoglobulin M
- LCMS
- liquid chromatography mass spectrometry
- M Protein
- membrane protein
- MALDI-ToF MS
- matrix-assisted laser desorption/ionization-time of flight mass spectrometry
- N Protein
- nucleocapsid protein
- NP
- nasopharyngeal
- RBD
- receptor binding domain
- RNA
- ribonucleic acid
- RT-PCR
- reverse transcriptase polymerase chain reaction
- S Protein
- spike protein
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- VEP
- viral envelope protein
- WHO
- world health organization
